Table 1.
Regimens used as the third-line treatment
| Regimen | All patients | Study cohort |
|---|---|---|
| Erlotinib | 29 (48%)a | 28 (48%) |
| Gefitinib | 1 (2%) | |
| Chemotherapy without platinum: | ||
| Pemetrexed | 1 (2%) | 1 (2%) |
| Gemcitabine | 7 (12%) | 7 (12%) |
| Vinorelbine | 7 (12%) | 7 (12%) |
| Taxanes | 5 (8%) | 5 (9%) |
| Platinum-based doublet: | ||
| Pemetrexed + Platinum | 4 (7%) | 4 (7%) |
| Gemcitabine + Platinum | 1 (2%) | 1 (2%) |
| Vinorelbine + Platinum | 2 (3%) | 2 (3%) |
| Taxanes + Platinum | 3 (5%) | 3 (5%) |
| Total | 60 | 58 |
Data are presented as n (%)
aIncluding one patient receiving both bevacizumab and erlotinib